Skip to Main Content

Paper Details

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Clinical Cancer Research
33
2021
FH, FH germline variant, FH mutation, FH mutations, FH-RCC, Fumarate, Fumarate Hydratase, Fumarate Hydratase-Deficient Renal Cell Carcinoma, Fumarate hydratase, Fumarate hydratase-deficient renal cell carcinoma, NF2, NF2 mutation, NF2 mutations, Patients, RCC, RCC syndrome, VEGF, clear, clear-cell RCC, genome, germline, hereditary leiomyomatosis, mTOR, metastatic FH-RCC, patients, tumor, tumors
Author NameAffiliation
Abraham Ari HakimiMemorial Sloan Kettering Cancer Center
  • 1 - 1

Datasets

Release 1.2